Emergent wins $24M anthrax contract
Emergent BioSolutions has won a $24.3 million contract with the Department of Health and Human Services to develop a new therapy for people exposed to anthrax. The biotech also makes the anthrax vaccine BioThrax. Emergent release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
